Prana Biotechnology is a biotechnology company focused on the research and development of treatments for Alzheimer's Disease and other major neurodegenerative disorders. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

The Company was incorporated in 1997 in Melbourne, Australia and listed on the on the Australian Stock Exchange in 2000 (ASX: PBT) and NASDAQ in 2002 (Nasdaq: PRAN).